JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Viatris Inc

Suletud

SektorTervishoid

10.36 0.58

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

10.3

Max

10.49

Põhinäitajad

By Trading Economics

Sissetulek

3B

-4.6M

Müük

328M

3.6B

Dividenditootlus

4.72

Kasumimarginaal

-0.128

Töötajad

32,000

EBITDA

2.9B

578M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+10.47% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

4.72%

2.33%

Järgmine tulemuste avaldamine

6. nov 2025

Järgmine dividendimakse kuupäev

12. dets 2025

Järgmine aktsia dividendi kuupäev (ex-date)

21. nov 2025

Turustatistika

By TradingEconomics

Turukapital

1.5B

12B

Eelmine avamishind

9.78

Eelmine sulgemishind

10.36

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

Viatris Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

9. okt 2025, 09:10 UTC

Kuumad aktsiad

Stocks to Watch Thursday: HSBC, PepsiCo, MP Materials -- WSJ

Võrdlus sarnastega

Hinnamuutus

Viatris Inc Prognoos

Hinnasiht

By TipRanks

10.47% tõus

12 kuu keskmine prognoos

Keskmine 11.5 USD  10.47%

Kõrge 15 USD

Madal 8 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Viatris Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

4 ratings

1

Osta

2

Hoia

1

Müü

Tehniline skoor

By Trading Central

8.48 / N/AToetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Very Strong Bullish Evidence

Pikk perspektiiv

Strong Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Viatris Inc

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
help-icon Live chat